Enoxaparin Administration in Myocardial Infarction After Dialysis

Introduction to Enoxaparin Administration

The American College of Cardiology recommends that patients initially treated with enoxaparin should not be switched to UFH and vice versa because of increased risk of bleeding, with a Level of Evidence A 3
The American Heart Association suggests that it is safe and appropriate to administer enoxaparin to a post-dialysis patient with myocardial infarction who received unfractionated heparin during dialysis, but you must avoid switching back and forth between the two agents, based on guidelines from the American College of Cardiology 1, 2

Enoxaparin demonstrates superior efficacy compared to UFH in STEMI patients, with a 17% reduction in the composite endpoint of death or nonfatal recurrent MI, according to the European Society of Cardiology 3
For patients with STEMI managed with fibrinolysis in the hospital, the American College of Cardiology recommends that it is reasonable to administer enoxaparin instead of UFH, with a Class IIa recommendation and Level of Evidence A 3
In the context of primary PCI, the European Heart Association suggests that enoxaparin may be preferred over UFH based on the ATOLL trial showing reductions in composite endpoints including death, recurrent MI, and urgent revascularization, with no indication of increased bleeding 4

For patients with creatinine clearance <30 mL/min, the American College of Cardiology recommends reducing enoxaparin to 1 mg/kg subcutaneously once daily, rather than the standard twice-daily dosing, with a Level of Evidence A 3
The initial 30 mg IV bolus used in younger patients should be omitted in patients ≥75 years or those with severe renal impairment, according to the American Heart Association 3

The American College of Cardiology recommends continuing aspirin regardless of bleeding risk, as the thrombotic risk in acute coronary syndrome outweighs bleeding risk, and aspirin dramatically reduces mortality, with a Class I recommendation and Level of Evidence A 1
The European Heart Association suggests administering clopidogrel 600 mg loading dose followed by 75 mg daily, or 150 mg daily for the first week in high-risk patients, based on guidelines from the European Society of Cardiology 4
For patients <75 years receiving fibrinolysis, the American College of Cardiology recommends a 300 mg clopidogrel loading dose is reasonable, with a Class IIa recommendation and Level of Evidence B 5

Once enoxaparin is initiated, the American College of Cardiology recommends not switching back to UFH, as this significantly increases bleeding risk, with a Level of Evidence A 3, 1
If bleeding complications occur requiring anticoagulation reversal, the American Heart Association suggests that protamine sulfate can partially reverse enoxaparin, approximately 60% reversal, based on guidelines from the American College of Cardiology 1

The European Heart Association suggests that bivalirudin may be considered as an alternative, particularly in patients undergoing PCI, with demonstrated superiority over UFH plus GP IIb/IIIa inhibitors in reducing bleeding while maintaining efficacy, based on the European Society of Cardiology guidelines 4
Fondaparinux is contraindicated in the setting of primary PCI, as it was associated with potential harm and increased catheter thrombosis in the OASIS-6 trial, according to the American College of Cardiology 4